GlassScriptPhysician profile
Andrew H Klompus
NPI 1215001771
$10,175.22
in general payments reported to CMS, 2019-2025
23 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $1,330 · 2021: $1,485 · 2022: $845 · 2023: $1,463 · 2024: $1,118 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,539 · Education: $16.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,539.39 |
| Education | $16.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,219.03 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $990.39 | 2023-2025 | Auvelity |
| Abbvie INC. | $909.55 | 2021-2025 | |
| Alkermes, INC. | $906.85 | 2021-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $902.92 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $896.21 | 2019-2025 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $855.30 | 2019-2025 | Trintellix |
| Allergan, INC. | $702.41 | 2019-2020 | |
| Bausch Health US, LLC | $573.90 | 2019-2025 | Aplenzin, Wellbutrin |
| Janssen Pharmaceuticals, INC | $446.19 | 2019-2022 | |
| Lundbeck LLC | $432.03 | 2019-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $385.39 | 2021-2025 | Uzedy |
| Sunovion Pharmaceuticals INC. | $200.36 | 2020-2021 | |
| Tris Pharma INC | $146.89 | 2020-2024 | Dyanavel Xr |
| Shire North American Group INC | $146.14 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $129.60 | 2019-2023 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $101.68 | 2025 | Qelbree |
| Avanir Pharmaceuticals, INC. | $91.62 | 2019-2020 | |
| Adlon Therapeutics L.P. | $48.88 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $26.57 | 2025 | Cobenfy |
| Bioxcel Therapeutics, INC. | $25.56 | 2023 | Igalmi |
| Jazz Pharmaceuticals INC. | $24.96 | 2021 | |
| Merck Sharp & Dohme LLC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Klompus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.